News & Innovations

News and innovations published by German exhibitors

  back to overview

Medigene publishes topline interim data from ongoing Phase I/II clinical trial with DC vaccines in AML patients

  • Topline-data from first half of treatment period (one year)

  • Very good feasibility of the manufacture of the vaccine from patient-derived cells

  • Excellent safety and tolerability profile

  • Preliminary data on overall survival and progression-free survival

  • Presentation of further details planned at an upcoming scientific conference

Further reading

Exhibitor: Medigene AG

OK

We use cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection